Basic information Safety Supplier Related

Nalfurafine

Basic information Safety Supplier Related

Nalfurafine Basic information

Product Name:
Nalfurafine
Synonyms:
  • TRK-820 HYDROCHLORIDE
  • (E)-N-((4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)-3-(furan-3-yl)-N-methylacrylamide
  • 17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride
  • 2-Propenamide, N-[(5a,6b)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-,hydrochloride (1:1), (2E)-
  • Nafurarphine Hydrochloride
  • Nalfurafina
  • AC 820
  • AC820
CAS:
152658-17-8
MF:
C28H33ClN2O5
MW:
513.02502
EINECS:
200-258-5
Product Categories:
  • Agonists
  • Chiral Reagents
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Neurochemicals
  • Pharmaceuticals
  • Inhibitors
Mol File:
152658-17-8.mol
More
Less

Nalfurafine Chemical Properties

Melting point:
207-217 °C
storage temp. 
Store at -20°C
solubility 
DMF: 16 mg/mL; DMSO: 33 mg/mL; Ethanol: 0.33 mg/mL; PBS (pH 7.2): 5 mg/mL
form 
A solid
More
Less

Nalfurafine Usage And Synthesis

Description

Pruritus (chronic itching) is a common symptom seen in 25-90% of uremic patients, especially those with chronic renal failure requiring hemodialysis. Nalfurafine hydrochloride is a new member of this class that exhibits an improved safety profile as compared with its predecessors in preclinical studies. It is a potent agonist for the κ-opioid receptor (Ki = 0.24 nM, EC50 = 0.008 nM, Imax = 91%), with substantially lower binding and agonism of the - or d-opioid receptors (Ki = 2.24 and 484 nM, EC50 = 1.66 and 21.3 nM, Imax = 53 and 78%, respectively). In vivo, nalfurafine hydrochloride demonstrates potent antipruritic activity against histamine-sensitive as well as histamine-resistant itch in mouse pruritogen-induced scratching models.
The most common adverse event associated with nalfurafine hydrochloride was insomnia or sleep disturbance, seen in 10% of the treated patients. Nalfurafine is structurally related to naltrexone (Revia ), an opioid receptor antagonist marketed for treating alcohol dependence. Nalfurafine is synthesized in two steps starting from naltrexone, via reductive amination with methylamine under catalytic hydrogenation conditions, and subsequent acylation with 3(E)-(3-furyl) acryloyl chloride.

Originator

Toray industries (Japan)

Uses

Nalfurafine hydrochloride was launched on March of 2009 in Japan as the first in class non-narcotic opioid drug for intractable itch caused by hemodialysis. It showed significant opioid κ-agonist activity and induced neither aversion nor preference in rats on the CPP (Conditioned Place Preference) test. A new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients.

brand name

Remitch

NalfurafineSupplier

Wuhan Jingkangen Biomedical Technology Co., Ltd Gold
Tel
00-13720134139 +86 -0-15871494362 13720134139
Email
orders@jknbiochem.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
Hangzhou Yuhao Chemical Technology Co., Ltd
Tel
0571-82693216
Email
info@yuhaochemical.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com